Want to see PDSB full AI Analyst Report?
PDSB Stock Chart & Stats
$0.22
-$0.02(-2.73%)
At close: 4:00 PM EDT
$0.22
-$0.02(-2.73%)
Day’s Range― - ―
52-Week Range$0.20 - $1.55
Previous Close$0.68
Volume202.05K
Average Volume (3M)44.10M
Market Cap
$41.89M
Enterprise Value$47.81M
Total Cash (Recent Filing)$5.60M
Total Debt (Recent Filing)$4.36M
Price to Earnings (P/E)―
Beta2.75
Next Earnings
Nov 12, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding55,971,336
10 Day Avg. Volume8,022,290
30 Day Avg. Volume44,104,405
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.76
Forecast
1Y Price Target
$5.00Price Target Upside2172.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising PDS0301 Clinical EfficacyEncouraging Phase 2 efficacy in difficult-to-treat metastatic colorectal cancer gives PDS0301 a potentially differentiated clinical profile. The results support advancement toward registrational development and may improve the company’s ability to attract partners or funding for later-stage trials.
Strong PDS0101 Phase 2 Results And Partner InterestThe published VERSATILE-002 results provide substantive validation for PDS0101 in HPV16-driven head and neck cancer. NantWorks’ exclusive one-year right to negotiate a license also indicates external interest, potentially supporting future development without relying entirely on internal resources.
Debt Retirement And Strategic FinancingRetiring the Yorkville note removes a stated debt obligation, while the PIPE supplies capital for working capital and clinical development. Together, these actions simplify near-term obligations and provide resources to advance PDS0301, although the financing remains equity-linked.
Bears Say
Pre-revenue Model With Persistent LossesPDS Biotechnology has no reported product revenue and continues to generate substantial losses, so its business model has not yet demonstrated commercial earnings power. Until a candidate is approved and monetized, ongoing development spending will continue to depend on financing or partnership proceeds.
Severely Weakened Balance SheetNegative equity and very high debt relative to assets materially reduce financial flexibility and increase solvency and refinancing risk. This weakens the company’s ability to absorb clinical setbacks or fund its pipeline internally, making future capital access important to sustaining operations.
Reliance On External Funding And Potential DilutionPDS Biotechnology must seek partners or additional external capital to advance PDS0101 while also funding PDS0301 development. The expanded share authorization increases financing flexibility but creates a durable risk of shareholder dilution as the pre-revenue company funds costly clinical programs.
PDS Biotechnology News
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $0.20 and its highest was $1.55 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
PDS Biotechnology Corporation’s market cap is $41.89M.
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Nov 12, 2026 which is in 37 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Aug 13, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.05.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -0.11.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 55,971,336 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -3.719%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Currently, no hedge funds are holding shares in PDSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (2172.73% Upside)
$5.00 (2172.73% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 25.1%
Last 30 Days ▲ 25.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
PDSB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
$5.00
▲(2172.73% Upside)
Technical Analysis
Ownership Overview
1.51%
Insiders
3.88% Mutual Funds
1.24% Other Institutional Investors
90.14% Public Companies and
Individual Investors